iBio
IBIO
53 hedge funds and large institutions have $7.63M invested in iBio in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 18 reducing their positions, and 27 closing their positions.
27% more call options, than puts
Call options by funds: $154K | Put options by funds: $121K
0.01% less ownership
Funds ownership: 0.04% → 0.03% (-0.01%)
24% less funds holding
Funds holding: 70 → 53 (-17)
50% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 18
56% less capital invested
Capital invested by funds: $17.5M → $7.63M (-$9.87M)
59% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 27
Top Buyers
| 1 |
Millennium Management
New York
|
+$1.39M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$547K |
| 3 |
E
Ergoteles
New York
|
+$309K |
| 4 |
Renaissance Technologies
New York
|
+$215K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$150K |
Top Sellers
| 1 |
BlackRock
New York
|
-$3.39M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.12M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$475K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$425K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$360K |
IBIO Hedge Fund Activity: Q2 2022 in Review
53 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q2 2022, worth a combined $7.63M — down 56% from $17.5M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of IBIO and 11 opened new positions — a net loss of 16 holders — while 18 trimmed existing stakes and 9 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.39M. The largest seller was BlackRock, cutting an estimated $3.39M.
- 53 institutional investors held iBio (IBIO) as of Q2 2022, down from 70 in Q1 2022.
- Funds reported $7.63M of iBio stock for Q2 2022, down 56% quarter-over-quarter.
- 11 funds opened new iBio positions in Q2 2022 and 27 closed out, a net change of -16 holders.
- The largest iBio buyer in Q2 2022 was Millennium Management, an estimated $1.39M added.
- The largest iBio seller in Q2 2022 was BlackRock, an estimated $3.39M sold.
Based on aggregated 13F filings for Q2 2022.